1. Home
  2. HSDT vs ALZN Comparison

HSDT vs ALZN Comparison

Compare HSDT & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSDT
  • ALZN
  • Stock Information
  • Founded
  • HSDT N/A
  • ALZN 2016
  • Country
  • HSDT United States
  • ALZN United States
  • Employees
  • HSDT N/A
  • ALZN N/A
  • Industry
  • HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • ALZN Medicinal Chemicals and Botanical Products
  • Sector
  • HSDT Health Care
  • ALZN Health Care
  • Exchange
  • HSDT Nasdaq
  • ALZN Nasdaq
  • Market Cap
  • HSDT 2.5M
  • ALZN 2.6M
  • IPO Year
  • HSDT N/A
  • ALZN 2021
  • Fundamental
  • Price
  • HSDT $0.21
  • ALZN $2.93
  • Analyst Decision
  • HSDT Hold
  • ALZN Strong Buy
  • Analyst Count
  • HSDT 1
  • ALZN 1
  • Target Price
  • HSDT N/A
  • ALZN $180.00
  • AVG Volume (30 Days)
  • HSDT 19.5M
  • ALZN 711.6K
  • Earning Date
  • HSDT 08-11-2025
  • ALZN 07-29-2025
  • Dividend Yield
  • HSDT N/A
  • ALZN N/A
  • EPS Growth
  • HSDT N/A
  • ALZN N/A
  • EPS
  • HSDT N/A
  • ALZN N/A
  • Revenue
  • HSDT $434,000.00
  • ALZN N/A
  • Revenue This Year
  • HSDT N/A
  • ALZN $322.64
  • Revenue Next Year
  • HSDT $75.13
  • ALZN N/A
  • P/E Ratio
  • HSDT N/A
  • ALZN N/A
  • Revenue Growth
  • HSDT N/A
  • ALZN N/A
  • 52 Week Low
  • HSDT $0.20
  • ALZN $2.75
  • 52 Week High
  • HSDT $24.00
  • ALZN $135.54
  • Technical
  • Relative Strength Index (RSI)
  • HSDT 20.97
  • ALZN 36.96
  • Support Level
  • HSDT $0.30
  • ALZN $2.75
  • Resistance Level
  • HSDT $0.38
  • ALZN $3.07
  • Average True Range (ATR)
  • HSDT 0.13
  • ALZN 0.19
  • MACD
  • HSDT 0.04
  • ALZN 0.05
  • Stochastic Oscillator
  • HSDT 0.46
  • ALZN 19.66

About HSDT Helius Medical Technologies Inc. (DE)

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Share on Social Networks: